Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 25

1.

Alteration by p11 of mGluR5 localization regulates depression-like behaviors.

Lee KW, Westin L, Kim J, Chang JC, Oh YS, Amreen B, Gresack J, Flajolet M, Kim D, Aperia A, Kim Y, Greengard P.

Mol Psychiatry. 2015 Dec;20(12):1546-56. doi: 10.1038/mp.2015.132. Epub 2015 Sep 15.

2.

Glutamatergic neurometabolites during early abstinence from chronic methamphetamine abuse.

O'Neill J, Tobias MC, Hudkins M, London ED.

Int J Neuropsychopharmacol. 2014 Oct 31;18(3). pii: pyu059. doi: 10.1093/ijnp/pyu059.

3.
4.

Pharmacological Treatments Inhibiting Levodopa-Induced Dyskinesias in MPTP-Lesioned Monkeys: Brain Glutamate Biochemical Correlates.

Morin N, Di Paolo T.

Front Neurol. 2014 Aug 5;5:144. doi: 10.3389/fneur.2014.00144. eCollection 2014. Review.

5.

Development of [(123)I]IPEB and [(123)I]IMPEB as SPECT Radioligands for Metabotropic Glutamate Receptor Subtype 5.

Kil KE, Zhu A, Zhang Z, Choi JK, Kura S, Gong C, Brownell AL.

ACS Med Chem Lett. 2014 Apr 6;5(6):652-6. doi: 10.1021/ml500007z. eCollection 2014 Jun 12.

6.

NMDA Receptor Modulators in the Treatment of Drug Addiction.

Tomek SE, Lacrosse AL, Nemirovsky NE, Olive MF.

Pharmaceuticals (Basel). 2013 Feb 6;6(2):251-68. doi: 10.3390/ph6020251.

7.

The role of metabotropic glutamate receptor 5 on the stromal cell-derived factor-1/CXCR4 system in oral cancer.

Kuribayashi N, Uchida D, Kinouchi M, Takamaru N, Tamatani T, Nagai H, Miyamoto Y.

PLoS One. 2013 Nov 13;8(11):e80773. doi: 10.1371/journal.pone.0080773. eCollection 2013.

8.

Potentiating mGluR5 function with a positive allosteric modulator enhances adaptive learning.

Xu J, Zhu Y, Kraniotis S, He Q, Marshall JJ, Nomura T, Stauffer SR, Lindsley CW, Conn PJ, Contractor A.

Learn Mem. 2013 Jul 18;20(8):438-45. doi: 10.1101/lm.031666.113.

9.

The metabotropic glutamate 5 receptor modulates extinction and reinstatement of methamphetamine-seeking in mice.

Chesworth R, Brown RM, Kim JH, Lawrence AJ.

PLoS One. 2013 Jul 4;8(7):e68371. doi: 10.1371/journal.pone.0068371. Print 2013.

10.

Fenobam sulfate inhibits cocaine-taking and cocaine-seeking behavior in rats: implications for addiction treatment in humans.

Keck TM, Yang HJ, Bi GH, Huang Y, Zhang HY, Srivastava R, Gardner EL, Newman AH, Xi ZX.

Psychopharmacology (Berl). 2013 Sep;229(2):253-65. doi: 10.1007/s00213-013-3106-9. Epub 2013 Apr 25.

11.

Studies of the metabotropic glutamate receptor 5 radioligand [¹¹C]ABP688 with N-acetylcysteine challenge in rhesus monkeys.

Sandiego CM, Nabulsi N, Lin SF, Labaree D, Najafzadeh S, Huang Y, Cosgrove K, Carson RE.

Synapse. 2013 Aug;67(8):489-501. doi: 10.1002/syn.21656. Epub 2013 Mar 27.

12.

Kinetic analysis of the metabotropic glutamate subtype 5 tracer [(18)F]FPEB in bolus and bolus-plus-constant-infusion studies in humans.

Sullivan JM, Lim K, Labaree D, Lin SF, McCarthy TJ, Seibyl JP, Tamagnan G, Huang Y, Carson RE, Ding YS, Morris ED.

J Cereb Blood Flow Metab. 2013 Apr;33(4):532-41. doi: 10.1038/jcbfm.2012.195. Epub 2012 Dec 19.

13.

Role of mGluR5 neurotransmission in reinstated cocaine-seeking.

Wang X, Moussawi K, Knackstedt L, Shen H, Kalivas PW.

Addict Biol. 2013 Jan;18(1):40-9. doi: 10.1111/j.1369-1600.2011.00432.x. Epub 2012 Feb 17.

14.

Reduced metabotropic glutamate receptor 5 in the Flinders Sensitive Line of rats, an animal model of depression: an autoradiographic study.

Kovačević T, Skelin I, Minuzzi L, Rosa-Neto P, Diksic M.

Brain Res Bull. 2012 Mar 10;87(4-5):406-12. doi: 10.1016/j.brainresbull.2012.01.010. Epub 2012 Jan 31.

15.

The clinical implications of mouse models of enhanced anxiety.

Sartori SB, Landgraf R, Singewald N.

Future Neurol. 2011 Jul 1;6(4):531-571.

16.

Overview of glutamatergic neurotransmission in the nervous system.

Niciu MJ, Kelmendi B, Sanacora G.

Pharmacol Biochem Behav. 2012 Feb;100(4):656-64. doi: 10.1016/j.pbb.2011.08.008. Epub 2011 Aug 26. Review.

17.

Operant sensation seeking requires metabotropic glutamate receptor 5 (mGluR5).

Olsen CM, Childs DS, Stanwood GD, Winder DG.

PLoS One. 2010 Nov 30;5(11):e15085. doi: 10.1371/journal.pone.0015085.

18.

Using glutamate homeostasis as a target for treating addictive disorders.

Reissner KJ, Kalivas PW.

Behav Pharmacol. 2010 Sep;21(5-6):514-22. doi: 10.1097/FBP.0b013e32833d41b2. Review.

19.

Deleterious effects of amyloid beta oligomers acting as an extracellular scaffold for mGluR5.

Renner M, Lacor PN, Velasco PT, Xu J, Contractor A, Klein WL, Triller A.

Neuron. 2010 Jun 10;66(5):739-54. doi: 10.1016/j.neuron.2010.04.029.

20.

Structure-activity relationships in a novel series of 7-substituted-aryl quinolines and 5-substituted-aryl benzothiazoles at the metabotropic glutamate receptor subtype 5.

Zhang P, Zou MF, Rodriguez AL, Conn PJ, Newman AH.

Bioorg Med Chem. 2010 May 1;18(9):3026-35. doi: 10.1016/j.bmc.2010.03.053. Epub 2010 Mar 27.

Supplemental Content

Support Center